ArticleACG case reports journal2026
Esophageal Crohn's Disease Successfully Treated With Risankizumab.
Article in ACG case reports journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal Crohn's disease (CD) is poorly studied despite being a significant predictor of intestinal CD progression and recurrence. Management has historically focused on steroids and acid suppression, with some success from immunosuppressants and biologics like antitumor necrosis factor-α agents. However, no specific guidelines exist for treating esophageal CD. Risankizumab, a human monoclonal antibody of interleukin-23, has shown promise in treating both induction and maintenance of remission in CD. This case series represents the first reported use of risankizumab in esophageal CD. Despite the absence of guidelines for esophageal CD management, these cases suggest that risankizumab may offer a valuable treatment option and should be strongly considered for managing esophageal CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.